MBX Biosciences, Inc. (MBX)
NASDAQ: MBX · Real-Time Price · USD
20.36
+0.09 (0.44%)
Dec 20, 2024, 4:00 PM EST - Market closed
MBX Biosciences Stock Forecast
Stock Price Forecast
The 4 analysts with 12-month price forecasts for MBX Biosciences stock have an average target of 37.25, with a low estimate of 30 and a high estimate of 44. The average target predicts an increase of 82.96% from the current stock price of 20.36.
Analyst Consensus: Strong Buy
* Price targets were last updated on Oct 8, 2024.
Analyst Ratings
The average analyst rating for MBX stock from 4 stock analysts is "Strong Buy". This means that analysts believe this stock is likely to perform very well in the near future and significantly outperform the market.
Recommendation Trends
Rating | Oct '24 | Nov '24 | Dec '24 |
---|---|---|---|
Strong Buy | 3 | 3 | 3 |
Buy | 1 | 1 | 1 |
Hold | 0 | 0 | 0 |
Sell | 0 | 0 | 0 |
Strong Sell | 0 | 0 | 0 |
Total | 4 | 4 | 4 |
Latest Forecasts
Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
---|---|---|---|---|---|---|---|
Jefferies | Jefferies | Strong Buy Initiates $35 | Strong Buy | Initiates | $35 | +71.91% | Oct 8, 2024 |
JP Morgan | JP Morgan | Buy Initiates $30 | Buy | Initiates | $30 | +47.35% | Oct 8, 2024 |
Stifel | Stifel | Strong Buy Initiates $40 | Strong Buy | Initiates | $40 | +96.46% | Oct 8, 2024 |
Guggenheim | Guggenheim | Strong Buy Initiates $44 | Strong Buy | Initiates | $44 | +116.11% | Oct 8, 2024 |
Financial Forecast
Revenue This Year
n/a
Revenue Next Year
n/a
EPS This Year
-13.42
from -2.66
EPS Next Year
-2.36
from -13.42
Revenue Forecast
Revenue | 2024 | 2025 | 2026 |
---|---|---|---|
High | n/a | n/a | n/a |
Avg | n/a | n/a | n/a |
Low | n/a | n/a | n/a |
Revenue Growth
Revenue Growth | 2024 | 2025 | 2026 |
---|---|---|---|
High | - | - | - |
Avg | - | - | - |
Low | - | - | - |
EPS Forecast
EPS | 2024 | 2025 | 2026 |
---|---|---|---|
High | -6.37 | -2.09 | -2.25 |
Avg | -13.42 | -2.36 | -2.45 |
Low | -26.91 | -2.48 | -2.84 |
EPS Growth
EPS Growth | 2024 | 2025 | 2026 |
---|---|---|---|
High | - | - | - |
Avg | - | - | - |
Low | - | - | - |
Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.